Related references
Note: Only part of the references are listed.Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients
Ronza Najjar-Debbiny et al.
CLINICAL INFECTIOUS DISEASES (2023)
Database resources of the National Center for Biotechnology Information in 2023
Eric W. Sayers et al.
NUCLEIC ACIDS RESEARCH (2023)
Implementation of pharmacogenomics into inpatient general medicine
Thomas Chen et al.
PHARMACOGENETICS AND GENOMICS (2023)
A comprehensive pharmacogenomic study indicates roles for SLCO1B1, ABCG2 and SLCO2B1 in rosuvastatin pharmacokinetics
Minna Lehtisalo et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)
The impact of endoxifen-guided tamoxifen dose reductions on endocrine side-effects in patients with primary breast cancer
S. M. Buijs et al.
ESMO OPEN (2023)
A MIR17HG-derived long noncoding RNA provides an essential chromatin scaffold for protein interaction and myeloma growth
Eugenio Morelli et al.
BLOOD (2023)
CYP2D6 and CYP2C8 pharmacogenetics and pharmacological interactions to predict imatinib plasmatic exposure in GIST patients
Chiara Dalle Fratte et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2023)
Cross-Ancestry Genome-Wide Association Study Defines the Extended CYP2D6 Locus as the Principal Genetic Determinant of Endoxifen Plasma Concentrations
Chiea Chuen Khor et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)
How to Run the Pharmacogenomics Clinical Annotation Tool (PharmCAT)
Binglan Li et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2023)
Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical RecommendationsS
Jingjing Yu et al.
DRUG METABOLISM AND DISPOSITION (2022)
Racial and Ethnic Differences in Drug Disposition and Response: Review of New Molecular Entities Approved Between 2014 and 2019
Anuradha Ramamoorthy et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Revisiting sORFs: overcoming challenges to identify and characterize functional microproteins
Dorte Schlesinger et al.
FEBS JOURNAL (2022)
Ultrarapid Nanopore Genome Sequencing in a Critical Care Setting
John E. Gorzynski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Prioritizing pharmacogenomics implementation initiates - survey of healthcare professionals
Teresa T. Ho et al.
PERSONALIZED MEDICINE (2022)
Interpreting coronary artery disease GWAS results: A functional genomics approach assessing biological significance
Katherine Hartmann et al.
PLOS ONE (2022)
Maturation and application of phenome-wide association studies
Shiying Liu et al.
TRENDS IN GENETICS (2022)
Independent Drug Action in Combination Therapy: Implications for Precision Oncology
Deborah Plana et al.
CANCER DISCOVERY (2022)
Comprehensive Analysis of Somatic Reversion Mutations in Homologous Recombination Repair (HRR) Genes in A Large Cohort of Chinese Pan-cancer Patients
Hong Zong et al.
JOURNAL OF CANCER (2022)
HLA Allele-Restricted Immune-Mediated Adverse Drug Reactions: Framework for Genetic Prediction
Kanoot Jaruthamsophon et al.
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY (2022)
Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype
John Henry McDermott et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2022)
Advancing Pharmacogenomics from Single-Gene to Preemptive Testing
Cyrine E. Haidar et al.
ANNUAL REVIEW OF GENOMICS AND HUMAN GENETICS (2022)
Pharmacogenomics: the low-hanging fruit in the personalized medicine tree
George P. Patrinos et al.
HUMAN GENETICS (2022)
Regulation of CYP3A4 and CYP3A5 by a lncRNA: a potential underlying mechanism explaining the association between CYP3A4*1G and CYP3A metabolism
Joseph M. Collins et al.
PHARMACOGENETICS AND GENOMICS (2022)
Association of CD274 (PD-L1) Copy Number Changes with Immune Checkpoint Inhibitor Clinical Benefit in Non-Squamous Non-Small Cell Lung Cancer
Karthikeyan Murugesan et al.
ONCOLOGIST (2022)
Idiosyncratic epistasis leads to global fitness-correlated trends
Christopher W. Bakerlee et al.
SCIENCE (2022)
An immune gene signature to predict prognosis and immunotherapeutic response in lung adenocarcinoma
Hongquan Chen et al.
SCIENTIFIC REPORTS (2022)
Somatic Mutations and Clonal Hematopoiesis as Drivers of Age-Related Cardiovascular Risk
Bernhard Haring et al.
CURRENT CARDIOLOGY REPORTS (2022)
Different Arrangement of Dopamine Receptors/NMDA Receptors Heterocomplexes in the Brain Regions of a Healthy Male, Female and Audiogenic Seizure-Prone Male Rats
Gigi Tevzadze et al.
American Journal of Biochemistry and Biotechnology (2022)
Genetic interactions drive heterogeneity in causal variant effect sizes for gene expression and complex traits
Roshni A. Patel et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2022)
Selective poly adenylation predicts the efficacy of immunotherapy in patients with lung adenocarcinoma by multiple omics research
Liusheng Wu et al.
ANTI-CANCER DRUGS (2022)
Targeted therapy for breast cancer: An overview of drug classes and outcomes
Aaron T. Jacobs et al.
BIOCHEMICAL PHARMACOLOGY (2022)
Discovery and validation of a transcriptional signature identifying homologous recombination-deficient breast, endometrial and ovarian cancers
Guillaume Beinse et al.
BRITISH JOURNAL OF CANCER (2022)
Legal reform to enhance global text and data mining research
Sean M. Fiil-Flynn et al.
SCIENCE (2022)
Using Circulating Tumor DNA in Colorectal Cancer: Current and Evolving Practices
Midhun Malla et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer
Andrea Cercek et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Genetics of drug-induced QT prolongation: evaluating the evidence for pharmacodynamic variants
Ana Lopez-Medina et al.
PHARMACOGENOMICS (2022)
Development of pharmacogenomic algorithm to optimize nateglinide dose for the treatment of type 2 diabetes mellitus
Shaik Mohammad Naushad et al.
PHARMACOLOGICAL REPORTS (2022)
Transcription Factors and ncRNAs Associated with CYP3A Expression in Human Liver and Small Intestine Assessed with Weighted Gene Co-Expression Network Analysis
Huina Huang et al.
BIOMEDICINES (2022)
Upstart DNA sequencers could be a ‘game changer’
Elizabeth Pennisi
SCIENCE (2022)
Validation of Pharmacogenomic Interaction Probability (PIP) Scores in Predicting Drug-Gene, Drug-Drug-Gene, and Drug-Gene-Gene Interaction Risks in a Large Patient Population
Kristine Ashcraft et al.
JOURNAL OF PERSONALIZED MEDICINE (2022)
Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments
[Anonymous]
ONCOTARGETS AND THERAPY (2022)
Why We Need to Take a Closer Look at Genetic Contributions to CYP3A Activity
Qinglian Zhai et al.
FRONTIERS IN PHARMACOLOGY (2022)
Characterization of ADME Gene Variation in Colombian Population by Exome Sequencing
Daniel Felipe Silgado-Guzman et al.
FRONTIERS IN PHARMACOLOGY (2022)
Artificial Intelligence, Healthcare, Clinical Genomics, and Pharmacogenomics Approaches in Precision Medicine
Habiba Abdelhalim et al.
FRONTIERS IN GENETICS (2022)
Rare genetic variants explain missing heritability in smoking
Seon-Kyeong Jang et al.
NATURE HUMAN BEHAVIOUR (2022)
APOBEC mutagenesis, kataegis, chromothripsis in EGFR-mutant osimertinib-resistant lung adenocarcinomas
P. Selenica et al.
ANNALS OF ONCOLOGY (2022)
APOBEC-Induced Mutagenesis in Cancer
Tony M. Mertz et al.
ANNUAL REVIEW OF GENETICS (2022)
Regulatory variants in a novel distal enhancer regulate the expression of CYP3A4 and CYP3A5
Joseph M. Collins et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2022)
Somatic Mutations and Alzheimer's Disease
[Anonymous]
JOURNAL OF ALZHEIMERS DISEASE (2022)
Liquid biopsy: current technology and clinical applications
Mina Nikanjam et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Predictive Biomarkers for Immunotherapy in Lung Cancer: Perspective From the International Association for the Study of Lung Cancer Pathology Committee
Mari Mino-Kenudson et al.
JOURNAL OF THORACIC ONCOLOGY (2022)
The genetic landscape of major drug metabolizing cytochrome P450 genes-an updated analysis of population-scale sequencing data
Yitian Zhou et al.
PHARMACOGENOMICS JOURNAL (2022)
Exclusion cycles: Reinforcing disparities in medicine
Ana Bracic et al.
SCIENCE (2022)
Molecular structures reveal synergistic rescue of Δ508 CFTR by Trikafta modulators
Karol Fiedorczuk et al.
SCIENCE (2022)
Functional regulatory variants implicate distinct transcriptional networks in dementia
Yonatan A. Cooper et al.
SCIENCE (2022)
Pharmacogenomic Profiling of Cisplatin-Resistant and -Sensitive Human Osteosarcoma Cell Lines by Multimodal Targeted Next Generation Sequencing
Claudia Maria Hattinger et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies
Anthony Turpin et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2022)
The All of Us Research Program: Data quality, utility, and diversity
Andrea H. Ramirez et al.
PATTERNS (2022)
Cancer proteogenomics: current impact and future prospects
D. R. Mani et al.
NATURE REVIEWS CANCER (2022)
CASPIAN: A method to identify chromatin topological associated domains based on spatial density cluster q
Haiyan Gong et al.
COMPUTATIONAL AND STRUCTURAL BIOTECHNOLOGY JOURNAL (2022)
Common genetic substrates of alcohol and substance use disorder severity revealed by pleiotropy detection against GWAS catalog in two populations
Qian Peng et al.
ADDICTION BIOLOGY (2021)
Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer
Kaysia Ludford et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2021)
Warfarin dosing algorithms: A systematic review
Innocent G. Asiimwe et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2021)
Proactive versus Reactive Therapeutic Drug Monitoring: Why, When, and How?
Manar Shmais et al.
Inflammatory Intestinal Diseases (2021)
50th anniversary of the first clinical trial with ICI 46,474 (tamoxifen): then what happened?
V. Craig Jordan
ENDOCRINE-RELATED CANCER (2021)
Considerations When Applying Pharmacogenomics to Your Practice
Wayne T. Nicholson et al.
MAYO CLINIC PROCEEDINGS (2021)
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives
Svetlana N. Aleksakhina et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Cytochrome P450 Enzymes and Drug Metabolism in Humans
Mingzhe Zhao et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)
Applications and challenges in therapeutic drug monitoring of cancer treatment: A review
Bushra Salman et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2021)
Drivers of dynamic intratumor heterogeneity and phenotypic plasticity
Antara Biswas et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2021)
PD-L1 polymorphisms predict survival outcomes in advanced non-small-cell lung cancer patients treated with PD-1 blockade
Hironori Yoshida et al.
EUROPEAN JOURNAL OF CANCER (2021)
Exome sequencing and analysis of 454,787 UK Biobank participants
Joshua D. Backman et al.
NATURE (2021)
A Decade of FDA-Approved Drugs (2010-2019): Trends and Future Directions
Dean G. Brown et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
CYP2D6 genotype and reduced codeine analgesic effect in real-world clinical practice
Daniel Carranza-Leon et al.
PHARMACOGENOMICS JOURNAL (2021)
A systematic review and meta-analysis of genotype-based and individualized data analysis of SLCO1B1 gene and statin-induced myopathy
Saowalak Turongkaravee et al.
PHARMACOGENOMICS JOURNAL (2021)
BIOMEDICINE NIH's 'precision nutrition' bet aims for individualized diets
Jocelyn Kaiser
SCIENCE (2021)
Modulating gut microbiota to treat cancer
Christopher H. Woelk et al.
SCIENCE (2021)
Genome-wide epistasis analysis for Alzheimer's disease and implications for genetic risk prediction
Hui Wang et al.
ALZHEIMERS RESEARCH & THERAPY (2021)
Transcriptome annotation in the cloud: complexity, best practices, and cost
Roberto Vera Alvarez et al.
GIGASCIENCE (2021)
Pharmacogenomic Biomarkers in US FDA-Approved Drug Labels (2000-2020)
Jeeyun A. Kim et al.
JOURNAL OF PERSONALIZED MEDICINE (2021)
Applications of Multi-omics Approaches for Exploring the Molecular Mechanism of Ovarian Carcinogenesis
Miaomiao Ye et al.
FRONTIERS IN ONCOLOGY (2021)
The Role of Omics Approaches to Characterize Molecular Mechanisms of Rare Ovarian Cancers: Recent Advances and Future Perspectives
Yashwanth Subbannayya et al.
BIOMEDICINES (2021)
Pharmacogenetics to guide cardiovascular drug therapy
Julio D. Duarte et al.
NATURE REVIEWS CARDIOLOGY (2021)
Detection of Microsatellite Instability: State of the Art and Future Applications in Circulating Tumour DNA (ctDNA)
Pauline Gilson et al.
CANCERS (2021)
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid for Tumors
Leigh Marcus et al.
CLINICAL CANCER RESEARCH (2021)
Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
Oliver Sartor et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
The Role of Mitochondrial DNA Variation in Drug Response: A Systematic Review
Samantha W. Jones et al.
FRONTIERS IN GENETICS (2021)
Combination Strategies to Augment Immune Check Point Inhibitors Efficacy-Implications for Translational Research
Hrishi Varayathu et al.
FRONTIERS IN ONCOLOGY (2021)
ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer
Jamie O. Brett et al.
BREAST CANCER RESEARCH (2021)
In SilicoTools and Approaches for the Prediction of Functional and Structural Effects of Single-Nucleotide Polymorphisms on Proteins: An Expert Review
Metin Yazar et al.
OMICS-A JOURNAL OF INTEGRATIVE BIOLOGY (2021)
Drugs and hepatic transporters: A review
Alexander Jetter et al.
PHARMACOLOGICAL RESEARCH (2020)
Cancer Chemotherapy: The Case for Therapeutic Drug Monitoring
Claire E. Knezevic et al.
THERAPEUTIC DRUG MONITORING (2020)
Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors
Neelima Vidula et al.
CLINICAL CANCER RESEARCH (2020)
Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine
Darshan Mehta et al.
DRUG DISCOVERY TODAY (2020)
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
Sylvie Lantuejoul et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Drug-drug-gene interactions and adverse drug reactions
Mustafa Adnan Malki et al.
PHARMACOGENOMICS JOURNAL (2020)
Pharmacogenomics of breast cancer: highlighting CYP2D6 and tamoxifen
Carmen W. H. Chan et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2020)
Use of Real-World Evidence in US Payer Coverage Decision-Making for Next-Generation Sequencing-Based Tests: Challenges, Opportunities, and Potential Solutions
Patricia A. Deverka et al.
VALUE IN HEALTH (2020)
Cis-acting regulatory elements regulating CYP3A4 transcription in human liver
Joseph M. Collins et al.
PHARMACOGENETICS AND GENOMICS (2020)
Pharmacogenetic factors affecting β-blocker metabolism and response
Cameron D. Thomas et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2020)
Pharmacogenomics and Personalized Medicine
Erika Cecchin et al.
GENES (2020)
The Promises and Challenges of Tumor Mutation Burden as an Immunotherapy Biomarker: A Perspective from the International Association for the Study of Lung Cancer Pathology Committee
Lynette Sholl et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
Susan M. Domchek et al.
LANCET ONCOLOGY (2020)
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing
Ashley Maynard et al.
CELL (2020)
Microbiome-derived inosine modulates response to checkpoint inhibitor immunotherapy
Lukas F. Mager et al.
SCIENCE (2020)
Clinical assays for assessment of homologous recombination DNA repair deficiency
Elizabeth H. Stover et al.
GYNECOLOGIC ONCOLOGY (2020)
Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance
Stephen J. Pettitt et al.
CANCER DISCOVERY (2020)
The GTEx Consortium atlas of genetic regulatory effects across human tissues
Francois Aguet et al.
SCIENCE (2020)
Poly(ADP-Ribose) Polymerase Inhibitors in Prostate Cancer: Molecular Mechanisms, and Preclinical and Clinical Data
Dawid Sigorski et al.
TARGETED ONCOLOGY (2020)
Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review
Sylvia D. Klomp et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Application of pharmacogenetics in oncology
Nelly N. Miteva-Marcheva et al.
BIOMARKER RESEARCH (2020)
Cyp2C19*2 Polymorphism Related to Clopidogrel Resistance in Patients With Coronary Heart Disease, Especially in the Asian Population: A Systematic Review and Meta-Analysis
Ying Sun et al.
FRONTIERS IN GENETICS (2020)
Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group
F. Mosele et al.
ANNALS OF ONCOLOGY (2020)
Combined Anti-Cancer Strategies Based on Anti-Checkpoint Inhibitor Antibodies
Josee Golay et al.
ANTIBODIES (2020)
CYP2D6 haplotypes with enhancer single-nucleotide polymorphism rs5758550 and rs16947 (*2 allele): implications for CYP2D6 genotyping panels
Balmiki Ray et al.
PHARMACOGENETICS AND GENOMICS (2019)
The role of pharmacogenomics in adverse drug reactions
Ramon Cacabelos et al.
EXPERT REVIEW OF CLINICAL PHARMACOLOGY (2019)
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
C. Luchini et al.
ANNALS OF ONCOLOGY (2019)
Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug?
Konstantinos Papamichael et al.
CURRENT OPINION IN GASTROENTEROLOGY (2019)
A Practical Guide for the Follow-Up of Patients with Advanced Basal Cell Carcinoma During Treatment with Hedgehog Pathway Inhibitors
Clio Dessinioti et al.
ONCOLOGIST (2019)
Precision Medicines' Impact on Orphan Drug Designation
Christine M. Mueller et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2019)
Priority index for human genetics and drug discovery
Robert M. Plenge
NATURE GENETICS (2019)
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma
C. Robert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Pharmacogenetics and Depression: A Critical Perspective
Filippo Corponi et al.
PSYCHIATRY INVESTIGATION (2019)
How liquid biopsies can change clinical practice in oncology
G. Siravegna et al.
ANNALS OF ONCOLOGY (2019)
Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma
Erica Leavitt et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
The Diverse Function of PD-1/PD-L Pathway Beyond Cancer
Weiting Qin et al.
FRONTIERS IN IMMUNOLOGY (2019)
Prognostic and predictive biomarkers in breast cancer: Past, present and future
Andrea Nicolini et al.
SEMINARS IN CANCER BIOLOGY (2018)
Perspective: APOBEC mutagenesis in drug resistance and immune escape in HIV and cancer evolution
S. Venkatesan et al.
ANNALS OF ONCOLOGY (2018)
Cytochrome P450 Structure, Function and Clinical Significance: A Review
Palrasu Manikandan et al.
CURRENT DRUG TARGETS (2018)
Clinical pharmacogenomics testing in the era of next generation sequencing: challenges and opportunities for precision medicine
Yuan Ji et al.
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS (2018)
The Pharmacologic Role and Clinical Utility of PCSK9 Inhibitors for the Treatment of Hypercholesterolemia
C. Michael White
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS (2018)
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer
Michael J. Overman et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Combined BRAF, EGFR, and MEK Inhibition in Patients with &ITBRAF&ITV600E-Mutant Colorectal Cancer
Ryan B. Corcoran et al.
CANCER DISCOVERY (2018)
Deoxycholic acid supplementation impairs glucose homeostasis in mice
Karolina E. Zaborska et al.
PLOS ONE (2018)
Combined genetic influence of the nicotinic receptor gene cluster CHRNA5/A3/B4 on nicotine dependence
Sung-Ha Lee et al.
BMC GENOMICS (2018)
Interactions Between Regulatory Variants in CYP7A1 (Cholesterol 7 alpha-Hydroxylase) Promoter and Enhancer Regions Regulate CYP7A1 Expression
Danxin Wang et al.
CIRCULATION-GENOMIC AND PRECISION MEDICINE (2018)
Standardizing terms for clinical pharmacogenetic test results: consensus terms from the Clinical Pharmacogenetics Implementation Consortium (CPIC)
Kelly E. Caudle et al.
GENETICS IN MEDICINE (2017)
The CHRNA5/CHRNA3/CHRNB4 Nicotinic Receptor Regulome: Genomic Architecture, Regulatory Variants, and Clinical Associations
Elizabeth S. Barrie et al.
HUMAN MUTATION (2017)
Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses
J. M. Campbell et al.
PHARMACOGENOMICS JOURNAL (2017)
Proteogenomic studies on cancer drug resistance: towards biomarker discovery and target identification
Shuyue Fu et al.
EXPERT REVIEW OF PROTEOMICS (2017)
Pharmacogenomics: Precision Medicine and Drug Response
Richard M. Weinshilboum et al.
MAYO CLINIC PROCEEDINGS (2017)
Genetic effects on gene expression across human tissues
Francois Aguet et al.
NATURE (2017)
Trends in GPCR drug discovery: new agents, targets and indications
Alexander S. Hauser et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Network Reconstruction Reveals that Valproic Acid Activates Neurogenic Transcriptional Programs in Adult Brain Following Traumatic Injury
Gerald A. Higgins et al.
PHARMACEUTICAL RESEARCH (2017)
Pharmacogenetics of drug-drug interaction and drug-drug-gene interaction: a systematic review on CYP2C9, CYP2C19 and CYP2D6
Muh Akbar Bahar et al.
PHARMACOGENOMICS (2017)
Deriving genomic diagnoses without revealing patient genomes
Karthik A. Jagadeesh et al.
SCIENCE (2017)
Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
Olga Kondrashova et al.
CANCER DISCOVERY (2017)
Analysis of Circulating Cell-Free DnA Identifies Multiclonal Heterogeneity of BRCA2 Reversion Mutations Associated with Resistance to PARP Inhibitors
David Quigley et al.
CANCER DISCOVERY (2017)
Circulating Cell-Free DNA to Guide Prostate Cancer Treatment with PARP Inhibition
Jane Goodall et al.
CANCER DISCOVERY (2017)
Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer
Britta Weigelt et al.
CLINICAL CANCER RESEARCH (2017)
Advances in understanding tumour evolution through single-cell sequencing
Jack Kuipers et al.
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER (2017)
Integrating pharmacogenomics into electronic health records with clinical decision support
J. Kevin Hicks et al.
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY (2016)
Variation in the Ability to Taste Bitter Thiourea Compounds: Implications for Food Acceptance, Dietary Intake, and Obesity Risk in Children
Kathleen L. Keller et al.
ANNUAL REVIEW OF NUTRITION, VOL 36 (2016)
Evaluating tools for transcription factor binding site prediction
Narayan Jayaram et al.
BMC BIOINFORMATICS (2016)
History of Orphan Drug Regulation-United States and Beyond
M. E. Haffner
CLINICAL PHARMACOLOGY & THERAPEUTICS (2016)
Data Sharing An Ethical and Scientific Imperative
Howard Bauchner et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2016)
Predicting drug-induced QT prolongation and torsades de pointes
Dan M. Roden
JOURNAL OF PHYSIOLOGY-LONDON (2016)
Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
David Planchard et al.
LANCET ONCOLOGY (2016)
Next generation sequencing: implications in personalized medicine and pharmacogenomics
Bahareh Rabbani et al.
MOLECULAR BIOSYSTEMS (2016)
NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity
Takaya Moriyama et al.
NATURE GENETICS (2016)
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients
Jacob J. Chabon et al.
NATURE COMMUNICATIONS (2016)
Effect of genetic variations on ticagrelor plasma levels and clinical outcomes
Christoph Varenhorst et al.
EUROPEAN HEART JOURNAL (2015)
Pharmacogenomics in the clinic
Mary V. Relling et al.
NATURE (2015)
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
D. T. Le et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Allele-Selective Transcriptome Recruitment to Polysomes Primed for Translation: Protein-Coding and Noncoding RNAs, and RNA Isoforms
Roshan Mascarenhas et al.
PLOS ONE (2015)
A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism
Anu Loukola et al.
PLOS GENETICS (2015)
UK Biobank: An Open Access Resource for Identifying the Causes of a Wide Range of Complex Diseases of Middle and Old Age
Cathie Sudlow et al.
PLOS MEDICINE (2015)
Genetics of Immune-Mediated Adverse Drug Reactions: a Comprehensive and Clinical Review
V. L. M. Yip et al.
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY (2015)
Progress towards the integration of pharmacogenomics in practice
Sean D. Mooney
HUMAN GENETICS (2015)
Functional characterization of CYP2D6 enhancer polymorphisms
Danxin Wang et al.
HUMAN MOLECULAR GENETICS (2015)
Development and Applications of CRISPR-Cas9 for Genome Engineering
Patrick D. Hsu et al.
CELL (2014)
Functional Gene Variants of CYP3A4
A. N. Werk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Genome-wide map of regulatory interactions in the human genome
Nastaran Heidari et al.
GENOME RESEARCH (2014)
Missing heritability of common diseases and treatments outside the protein-coding exome
Wolfgang Sadee et al.
HUMAN GENETICS (2014)
Common CYP2D6 polymorphisms affecting alternative splicing and transcription: long-range haplotypes with two regulatory variants modulate CYP2D6 activity
Danxin Wang et al.
HUMAN MOLECULAR GENETICS (2014)
Ethnicity-specific pharmacogenetics: the case of warfarin in African Americans
W. Hernandez et al.
PHARMACOGENOMICS JOURNAL (2014)
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
Johnathan A. Watkins et al.
BREAST CANCER RESEARCH (2014)
Whole transcriptome RNA-Seq allelic expression in human brain
Ryan M. Smith et al.
BMC GENOMICS (2013)
Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study
Minoli A. Perera et al.
LANCET (2013)
Chromatin connectivity maps reveal dynamic promoter-enhancer long-range associations
Yubo Zhang et al.
NATURE (2013)
CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy
Laure Elens et al.
PHARMACOGENOMICS (2013)
Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation
Ulrich M. Zanger et al.
PHARMACOLOGY & THERAPEUTICS (2013)
Initial Assessment of Tumor Regrowth After Vismodegib in Advanced Basal Cell Carcinoma
Anne Lynn S. Chang et al.
ARCHIVES OF DERMATOLOGY (2012)
Pharmacogenomics Knowledge for Personalized Medicine
M. Whirl-Carrillo et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Genome-wide association analysis of coffee drinking suggests association with CYP1A1/CYP1A2 and NRCAM
N. Amin et al.
MOLECULAR PSYCHIATRY (2012)
The long-range interaction landscape of gene promoters
Amartya Sanyal et al.
NATURE (2012)
An integrated encyclopedia of DNA elements in the human genome
Ian Dunham et al.
NATURE (2012)
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Marco Gerlinger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
Jonathan Ledermann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Personalized medicine is more than genomic medicine: confusion over terminology impedes progress towards personalized healthcare
Leigh Ann Simmons et al.
PERSONALIZED MEDICINE (2012)
Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants
Emily R. Holzinger et al.
PHARMACOGENETICS AND GENOMICS (2012)
Mining the Unknown: A Systems Approach to Metabolite Identification Combining Genetic and Metabolic Information
Jan Krumsiek et al.
PLOS GENETICS (2012)
Spreading Chromatin into Chemical Biology
C. David Allis et al.
CHEMBIOCHEM (2011)
Pharmacogenomics of the RNA World: Structural RNA Polymorphisms in Drug Therapy
W. Sadee et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Intronic polymorphism in CYP3A4 affects hepatic expression and response to statin drugs
D. Wang et al.
PHARMACOGENOMICS JOURNAL (2011)
Pharmacogenetics, Pharmacogenomics, and Individualized Medicine
Qiang Ma et al.
PHARMACOLOGICAL REVIEWS (2011)
PARP inhibitors: its role in treatment of cancer
Alice Chen
Chinese Journal of Cancer (2011)
Interfering with Resistance to Smoothened Antagonists by Inhibition of the PI3K Pathway in Medulloblastoma
Silvia Buonamici et al.
SCIENCE TRANSLATIONAL MEDICINE (2010)
Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution
Sohrab P. Shah et al.
NATURE (2009)
Inhibition of the Hedgehog Pathway in Advanced Basal-Cell Carcinoma.
Daniel D. Von Hoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Potential etiologic and functional implications of genome-wide association loci for human diseases and traits
Lucia A. Hindorff et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Smoothened Mutation Confers Resistance to a Hedgehog Pathway Inhibitor in Medulloblastoma
Robert L. Yauch et al.
SCIENCE (2009)
Regulatory polymorphism in vitamin K epoxide reductase complex subunit 1 (VKORC1) affects gene expression and warfarin dose requirement
Danxin Wang et al.
BLOOD (2008)
Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases
Michael C. Heinrich et al.
CLINICAL CANCER RESEARCH (2008)
Polymorphisms affecting gene transcription and mRNA processing in pharmacogenetic candidate genes:: detection through allelic expression imbalance in human target tissues
Andrew D. Johnson et al.
PHARMACOGENETICS AND GENOMICS (2008)
v-Src-mediated down-regulation of SSeCKS metastasis suppressor gene promoter by the recruitment of HDAC1 into a USF1-Sp1-Sp3 complex
Yahao Bu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2007)
Molecular mechanism of basal CYP3A4 regulation by hepatocyte nuclear factor 4α :: Evidence for direct regulation in the intestine
Heike Tegude et al.
DRUG METABOLISM AND DISPOSITION (2007)
MicroRNA-192 in diabetic kidney glomeruli and its function in TGF-β-induced collagen expression via inhibition of E-box repressors
Mitsuo Kato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
Transcriptional regulation and expression of CYP3A4 in hepatocytes
Celia P. Martinez-Jimenez et al.
CURRENT DRUG METABOLISM (2007)
Allelic mRNA expression of X-linked monoamine oxidase a (MAOA) in human brain:: dissection of epigenetic and genetic factors
Julia K. Pinsonneault et al.
HUMAN MOLECULAR GENETICS (2006)
Multidrug resistance polypeptide 1 (MDR1, ABCB1) variant 3435C>T affects mRNA stability
DX Wang et al.
PHARMACOGENETICS AND GENOMICS (2005)
Impact of the CYP2D6 ultra-rapid metabolizer genotype on doxepin pharmacokinetics and serotonin in platelets
J Kirchheiner et al.
PHARMACOGENETICS AND GENOMICS (2005)
Strategies and methods for research on sex differences in brain and behavior
JB Becker et al.
ENDOCRINOLOGY (2005)
Single base pair change in the long-range Sonic hedgehog limb-specific enhancer is a genetic basis for preaxial polydactyly
SA Maas et al.
DEVELOPMENTAL DYNAMICS (2005)
Identification of a novel polymorphic enhancer of the human CYP3A4 gene
K Matsumura et al.
MOLECULAR PHARMACOLOGY (2004)
Membrane transporters and channels:: Role of the transportome in cancer chemosensitivity and chemoresistance
Y Huang et al.
CANCER RESEARCH (2004)
The three Es of cancer immunoediting
GP Dunn et al.
ANNUAL REVIEW OF IMMUNOLOGY (2004)
Looping and interaction between hypersensitive sites in the active β-globin locus
B Tolhuis et al.
MOLECULAR CELL (2002)
Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism
YS Lin et al.
MOLECULAR PHARMACOLOGY (2002)
Potential role of pharmacogenomics in reducing adverse drug reactions - A systematic review
KA Phillips et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Association of GSTT1 non-null and NAT1 slow/rapid genotypes with von Hippel-Lindau tumour suppressor gene transversions in sporadic renal cell carcinoma
C Gallou et al.
PHARMACOGENETICS (2001)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)